Conditions

The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.

Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.

Results from two ODYSSEY studies indicate the favorable lipid lowering effects of Alirocumab, a PCSK9 inhibitor, in type 2 diabetes patients can potentially reduce the risk of cardiovascular disease.

In this week's Homerun Slides, a summary of the clinical trials assessing the impact of intensive therapy in type 2 diabetes.

New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.

In addition to psychosocial risk factors, disease related factors may also be contributing to bulimic symptoms.

Placing newborns in prospective studies to conduct genetic screenings with follow up may reduce the risk of DKA at diagnosis of type 1.

After 30 years of follow-up studies, DCCT/EDIC study gives findings regarding risk of severe hypoglycemia.

Results determined for 3-year study of liraglutide versus placebo diabetes risk reduction and weight management in individuals with prediabetes.

New research suggests HbA1c may be the most effective method to identify patients with undiagnosed prediabetes.